6VVY

Mycobacterium tuberculosis WT RNAP transcription open promoter complex with Sorangicin

6VVY の概要

• エントリーDOI: 10.2210/pdb6vvy/pdb
• EMDBエントリー: 21406 21407 21408 21409
• 分子名称: DNA-directed RNA polymerase subunit alpha, SORANGICIN A, ZINC ION, ... (12 entities in total)
• 機能のキーワード: initiation, transcription bubble, antibiotic, sorangicin, open promoter complex, transcription, transferase-dna-antibiotic complex, transferase/dna/antibiotic
• 由来する生物種: Mycobacterium tuberculosis; 詳細
• タンパク質・核酸の鎖数: 10
• 化学式量合計: 511125.78

構造登録者

Lilic, M.,Boyaci, H.,Chen, J.,Darst, S.A.,Campbell, E.A. (登録日: 2020-02-18, 公開日: 2020-10-21, 最終更新日: 2024-03-06)

主引用文献

Lilic, M.,Chen, J.,Boyaci, H.,Braffman, N.,Hubin, E.A.,Herrmann, J.,Muller, R.,Mooney, R.,Landick, R.,Darst, S.A.,Campbell, E.A.
The antibiotic sorangicin A inhibits promoter DNA unwinding in a Mycobacterium tuberculosis rifampicin-resistant RNA polymerase.
Proc.Natl.Acad.Sci.USA, 117:30423-30432, 2020

PubMed Abstract: Rifampicin (Rif) is a first-line therapeutic used to treat the infectious disease tuberculosis (TB), which is caused by the pathogen (). The emergence of Rif-resistant (Rif) presents a need for new antibiotics. Rif targets the enzyme RNA polymerase (RNAP). Sorangicin A (Sor) is an unrelated inhibitor that binds in the Rif-binding pocket of RNAP. Sor inhibits a subset of Rif RNAPs, including the most prevalent clinical Rif RNAP substitution found in infected patients (S456>L of the β subunit). Here, we present structural and biochemical data demonstrating that Sor inhibits the wild-type RNAP by a similar mechanism as Rif: by preventing the translocation of very short RNAs. By contrast, Sor inhibits the Rif S456L enzyme at an earlier step, preventing the transition of a partially unwound promoter DNA intermediate to the fully opened DNA and blocking the template-strand DNA from reaching the active site in the RNAP catalytic center. By defining template-strand blocking as a mechanism for inhibition, we provide a mechanistic drug target in RNAP. Our finding that Sor inhibits the wild-type and mutant RNAPs through different mechanisms prompts future considerations for designing antibiotics against resistant targets. Also, we show that Sor has a better pharmacokinetic profile than Rif, making it a suitable starting molecule to design drugs to be used for the treatment of TB patients with comorbidities who require multiple medications.

PubMed: 33199626
DOI: 10.1073/pnas.2013706117

実験手法

ELECTRON MICROSCOPY (3.42 Å)